MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling

Leukemia

Volumn 29, Issue 2, 2015, Pages 494-497

  Kollmann, K ^a   Nangalia, J ^a,b,c   Warsch, W ^a   Quentmeier, H ^d   Bench, A ^c   Boyd, E ^c   Scott, M ^c   Drexler, H G ^d   Green, A R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d LEIBNIZ INSTITUTE DSMZ GERMAN COLLECTION OF MICROORGANISMS AND CELL CULTURES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALRETICULIN; JANUS KINASE 2; RUXOLITINIB; STAT3 PROTEIN; STAT5 PROTEIN; THAPSIGARGIN; TOFACITINIB; CD15 ANTIGEN; JAK2 PROTEIN, HUMAN;

ALLELE; BONE MARROW CULTURE; CALCIUM BINDING; CALCIUM DEPLETION; CALCIUM HOMEOSTASIS; COMPARATIVE STUDY; ENDOPLASMIC RETICULUM; EXON; HUMAN; LETTER; MUTATION; MYELOPROLIFERATIVE NEOPLASM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; AGED; CYTOPLASM; DNA SEQUENCE; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; GENETICS; INFLAMMATION; METABOLISM; TUMOR CELL LINE;

AGED; ALLELES; ANTIGENS, CD15; CALRETICULIN; CELL LINE, TUMOR; CYTOPLASM; EXONS; FEMALE; GENE DELETION; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; JANUS KINASE 2; MUTATION; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR;

EID: 84922471899     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.285     Document Type: Letter

References (16)

1. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
2. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
3. Tefferi A, Thiele J, Vannucchi AM, Barbui T. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28: 1407-1413.
4. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS et al. Use of JAK inhibitors in the management of myelo fibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol 2014; e-pub ahead of print 25 June 2014; doi:10.1111/bjh.12985.
5. Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR et al. Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Br J Haematol 2014; e-pub ahead of print 17 June 2014; doi:10.1111/bjh.12986.
6. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelo fibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
7. Yoshida H, Kondo M, Ichihashi T, Hashimoto N, Inazawa J, Ohno R et al. A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification. Cancer Genet Cytogenet 1998; 100: 21-24.
8. Guglielmelli P, Nangalia J, Green AR, Vannucchi AM. CALR mutations in myeloproliferative neoplasms: hidden behind the reticulum. Am J Hematol 2014; 89: 453-456.
9. Michalak M, Groenendyk J, Szabo E, Gold LI, Opas M. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 2009; 417: 651-666.
10. Wictome M, Henderson I, Lee AG, East JM. Mechanism of inhibition of the calcium pump of sarcoplasmic reticulum by thapsigargin. Biochem J 1992; 283: 525-529.
11. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel JP, Brunel J-P, Mermel CH et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123: e123-e133.
12. Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B et al. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol 2007; 35: 1695-1703.
13. Puigdecanet E, Espinet B, Lozano JJ, Sumoy L, Bellosillo B, Arenillas L et al. Gene expression profi ling distinguishes JAK2V617F-negative from JAK2V617Fpositive patients in essential thrombocythemia. Leukemia 2008; 22: 1368-1376.
14. Passamonti F, Caramazza D, Maf fioli M. JAK inhibitor in CALR-mutant myelofibrosis. N Engl J Med 2014; 370: 1168-1169.
15. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
16. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.